Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
48
PHBI Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
64.41%
Day range:
$0.0021 - $0.0026
52-week range:
$0.0007 - $0.0034
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
633.48x
P/B ratio:
--
Volume:
2.3M
Avg. volume:
2.7M
1-year change:
23.53%
Market cap:
$1.1M
Revenue:
$3.4K
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Pharmagreen Biotech, Inc. has -- downside to fair value with a price target of -- per share.
PHBI vs. S&P 500
-
Over the past 5 trading days, Pharmagreen Biotech, Inc. has underperformed the S&P 500 by -28.54% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Pharmagreen Biotech, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pharmagreen Biotech, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Pharmagreen Biotech, Inc. reported revenues of $300.
Earnings Growth
-
Pharmagreen Biotech, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Pharmagreen Biotech, Inc. reported earnings per share of --.
Enterprise value:
1.4M
EV / Invested capital:
--
Price / LTM sales:
633.48x
EV / EBIT:
--
EV / Revenue:
618.21x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-71.58x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$500
Return On Assets:
-240.07%
Net Income Margin (TTM):
-10654.55%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-16266.67%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | $1.6K | $4.3K | $2.3K | $600 | $300 | |
| Gross Profit | -$3.5K | -$100 | -$500 | $100 | -$1.3K | |
| Operating Income | -$558.6K | -$288.5K | -$209.4K | -$57.1K | -$48.8K | |
| EBITDA | -$558.6K | -$288.5K | -$209.5K | -$57.1K | -$48.8K | |
| Diluted EPS | -$0.00 | -$0.00 | -$0.00 | -$0.00 | $0.00 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $19.3K | $191.2K | $51.5K | $9.1K | $96.6K | |
| Total Assets | $19.3K | $191.2K | $140.3K | $97.9K | $96.6K | |
| Current Liabilities | $1.8M | $2M | $2.2M | $2.3M | $2.7M | |
| Total Liabilities | $1.9M | $2.1M | $2.3M | $2.4M | $2.7M | |
| Total Equity | -$1.8M | -$1.9M | -$2.2M | -$2.3M | -$2.6M | |
| Total Debt | $229.4K | $348.2K | $270.2K | $225.9K | $186.5K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$138.5K | -$56.7K | -$19K | -$700 | -$3.8K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $84K | $28K | $25.7K | $500 | $3.1K | |
| Free Cash Flow | -$138.6K | -$56.8K | -$19K | -$700 | -$3.8K | |
PHBI
Sector
Market Cap
$1.1M
$27.9M
Price % of 52-Week High
61.77%
50.56%
Dividend Yield
0%
0%
Shareholder Yield
0.05%
-1.55%
1-Year Price Total Return
23.53%
-17.49%
Beta (5-Year)
1.558
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0027
200-day SMA
Buy
Level
$0.0013
Bollinger Bands (100)
Buy
Level
0.0015 - 0.0015
Chaikin Money Flow
Buy
Level
215.2M
20-day SMA
Sell
Level
$0.0025
Relative Strength Index (RSI14)
Sell
Level
45.6674
ADX Line
Buy
Level
32.3675
Williams %R
Buy
Level
-86.6667
50-day SMA
Sell
Level
$0.0021
MACD (12, 26)
Buy
Level
0.0002
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
292M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-249.1676)
Sell
CA Score
(Annual)
Level (-122.2864)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (295.8009)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pharmagreen Biotech, Inc. is a biotech sciences company with specialized products and services in the booming cannabis industry. The firm's products focus on manufacturing and marketing of cannabis products for medical and recreational markets. Its services include Good Manufacturing Practices (GMP) certification for its Tissue Culture facilities, Cold Storage of plantlets as well as Nurseries. The company was founded on November 26, 2007 and is headquartered in Coquitlam, Canada.
Stock Forecast FAQ
In the current month, PHBI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PHBI average analyst price target in the past 3 months is --.
-
Where Will Pharmagreen Biotech, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pharmagreen Biotech, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Pharmagreen Biotech, Inc.?
Analysts are divided on their view about Pharmagreen Biotech, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pharmagreen Biotech, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Pharmagreen Biotech, Inc.'s Price Target?
The price target for Pharmagreen Biotech, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PHBI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pharmagreen Biotech, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PHBI?
You can purchase shares of Pharmagreen Biotech, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pharmagreen Biotech, Inc. shares.
-
What Is The Pharmagreen Biotech, Inc. Share Price Today?
Pharmagreen Biotech, Inc. was last trading at $0.0000 per share. This represents the most recent stock quote for Pharmagreen Biotech, Inc.. Yesterday, Pharmagreen Biotech, Inc. closed at $0.0021 per share.
-
How To Buy Pharmagreen Biotech, Inc. Stock Online?
In order to purchase Pharmagreen Biotech, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PHBI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PHBI
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
--
1.81x
Price / LTM sales
633.48x
1.59x
Growth Metrics
PHBI
Sector
Revenue growth
-45.53%
4.6%
Earnings growth
--
10.88%
Revenue (5-year growth)
--
6.45%
Earnings forecast
--
-$0.21
Profitability
PHBI
Sector
Profitability FY 2024
$1.1K
$3.6M
Return on invested capital
--
-31.84%
Return on assets
-240.07%
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Dec
31
Next Earnings Date
Dec
31
Estimated Next Earnings Date
Apr
1
Balance Sheet
PHBI
Sector
Total cash
$600
$26.3M
Short term investments
--
$25.7M
Total assets
$97.7K
$76.9M
Long term debt
$354.3K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
